Monoclonal antibody · Immune activation, directed at interleukin-18-binding protein (IL18BP) · developed by Compugen
GS-0321 is a humanized IgG4 monoclonal antibody that binds interleukin-18-binding protein (IL18BP), releasing IL-18 from its complex with IL18BP. Freed IL-18 activates the IL-18 receptor on T cells and natural killer cells, inducing interferon-gamma secretion. It is studied in cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06759649 | Phase 1 | Neoplasm | Recruiting | CGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cancer, Malignant TumorsNeoplasm
See CGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CGEN catalysts and pipeline →